Abstract 175P
Background
Advanced gastric adenocarcinoma with both lymph node and peritoneal metastasis has notoriously poor prognosis. However, molecular mechanism of the metastatic process and potential therapeutic targets remain unknown, hence limiting the development of new therapies.
Methods
We recruited 13 treatment-naïve patients who had gastric adenocarcinoma with concurrent lymph node and peritoneal metastasis. DNA and RNA were extracted from tumor biopsy samples collected from the stomach, lymph node and peritoneum, together with 2 mL of peripheral blood for each patient. Whole exome sequencing (WES) and transcriptome sequencing were performed to generate a comprehensive genomic dataset of our cohort.
Results
Analysis of WES data showed that TP53 and CDH1 were the most frequently mutated genes in both the primary and metastatic tumors. All patients had low tumor mutational burden, but 31% (n=4) showed high level of chromosomal instability (CIN). By constructing tumor phylogenetic trees for each patient, we found evidence supporting two distinct processes of peritoneal dissemination that involved either lymphatic system (n=5) or direct seeding into the peritoneal cavity (n=4). In the RNA sequencing analysis, epithelial-mesenchymal transition (EMT) pathway was found the most significantly altered and segregated the patients into the EMT-high group (n=10) that upregated genes in the EMT pathway, and the non-EMT-high group (n=3).
Conclusions
Multi-omics profiling in this study revealed mutational signature and altered signaling pathways in lymph node and peritoneal metastasis. The results could help identify distinct molecular subtypes among patients, laying foundation for the development of molecular-guided therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute, Ho Chi Minh city, Vietna.
Funding
Gene Solutions JSC, Ho Chi Minh city, Vietnam.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract